[1] Warren MS, Hughes SG, Singleton W, Yamashita M, Genovese MC. Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.Arthritis Res Ther. 2015;17(1):80. DOI:
10.1186/s13075-015-0578-5[2] Noveck R, Stroes ES, Flaim JD, et al. Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers.J Am Heart Assoc. 2014;3(4):e001084. DOI:
10.1161/JAHA.114.001084